|
| Wednesday, October 9, 2024 |
|
|
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing |
| Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that dosing has begun, for human pilot study #3 (the "Study"), investigating a DehydraTECH-processed version of the dual action GLP-1 (glucagon-like peptide) + GIP (glucose-dependent insulinotropic peptide) Zepbound (tirzepatide) in an oral dose format. more info >> |
|
| Tuesday, October 8, 2024 |
|
|
Lexaria Updates Current GLP-1 Market |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, provides an update on recent glucagon-like peptide-1 ("GLP-1") receptor agonist market sector advancements. more info >> |
|
| Tuesday, October 1, 2024 |
|
|
Lexaria Appoints Michael Shankman as Chief Financial Officer |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Michael Shankman, CPA, as Chief Financial Officer (CFO) effective immediately. As a member of the executive leadership team, Mr. Shankman will lead the Company's financial operations. more info >> |
|
| Friday, September 27, 2024 |
|
|
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3 |
| Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that approval has been received from an independent review board, for human pilot study #3 (the "Study"), investigating a DehydraTECH-processed version of the dual action GLP-1 (glucagon-like peptide) + GIP (glucose-dependent insulinotropic peptide) tirzepatide in an oral dose format. more info >> |
|
| Thursday, September 5, 2024 |
|
|
Lexaria Releases Strategic Letter from the Outgoing CEO |
| Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this letter from outgoing Chief Executive Officer ("CEO") Chris Bunka as a strategic update to all stakeholders. more info >> |
|
|
Lexaria Welcomes Industry Veteran as New CEO |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that Chris Bunka, Chief Executive Officer ("CEO") of the Company, is stepping aside for the appointment of Richard Christopher as the new CEO, effective August 31, 2024. more info >> |
|
| Tuesday, September 3, 2024 |
|
|
Lexaria Enters a Material Transfer Agreement for DehydraTECH Research |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has entered into a Material Transfer Agreement with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECHTM technology in a pre-clinical setting. more info >> |
|
| Thursday, August 29, 2024 |
|
|
Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus Oral Capsules |
| more info >> |
|
| Tuesday, August 27, 2024 |
|
|
First Results From Lexaria's Second GLP-1 Human Pilot Study |
| more info >> |
|
| Thursday, August 22, 2024 |
|
|
Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received and can now report on 8-week body weight results from ongoing animal study WEIGHT-A24-1 (the "Study"). more info >> |
|
|
|
|
